Description
Microbiosensor is using the QuickCheck® technology, first
developed for peritoneal dialysis patients, to tackle other unmet infection
diagnostic needs. For example, with patients who have advanced liver disease
(cirrhosis).
Once liver disease progresses to the decompensated stage,
patients commonly suffer from a build-up of fluid in the peritoneal cavity.
Infection of this fluid due to spontaneous bacterial peritonitis (SBP) is a
significant risk for such patients – and carries a 50% mortality rate in the
UK. Current diagnosis often takes over 24-hours and therefore instant diagnosis
and an earlier start on treatment could have a major benefit for these
patients. QuickCheck® SBP is being developed to tackle this unmet need. We plan
to have prototype devices ready for clinical evaluation in 2023.
Recent autopsy data suggest that the prevalence of cirrhosis
is between 5% and 9% of the adult population globally. Approximately 50M people
globally are thought to have advanced liver disease or cirrhosis.